

Lucy H Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1741587/publications.pdf>

Version: 2024-02-01

47
papers

1,687
citations

411340
20
h-index

325983
40
g-index

48
all docs

48
docs citations

48
times ranked

2331
citing authors

#	ARTICLE	IF	CITATIONS
1	Endoscopic Cyclophotocoagulation in Boston Keratoprosthesis Type II. <i>Ophthalmology Glaucoma</i> , 2022, 5, 120-123.	0.9	0
2	Effects of <i>cannabis</i> and its components on the retina: a systematic review. <i>Cutaneous and Ocular Toxicology</i> , 2020, 39, 1-9.	0.5	6
3	Sympathetic Ophthalmia. <i>Retina Atlas</i> , 2020, , 59-65.	0.0	0
4	Biallelic -associated retinal dystrophies: Expanding the mutational and clinical spectrum. <i>Molecular Vision</i> , 2020, 26, 423-433.	1.1	4
5	<i>Toxoplasma</i> GRA15 Activates the NF- κ B Pathway through Interactions with TNF Receptor-Associated Factors. <i>MBio</i> , 2019, 10, .	1.8	56
6	Serotyping of <i>Toxoplasma gondii</i> Infection Using Peptide Membrane Arrays. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 408.	1.8	20
7	Treatment of Refractory Acute Retinal Necrosis with Intravenous Foscarnet or Cidofovir. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 199-203.	1.0	16
8	Case 37-2018: A 23-Year-Old Woman with Vision Loss. <i>New England Journal of Medicine</i> , 2018, 379, 2152-2159.	13.9	0
9	Hydroxychloroquine retinopathy – implications of research advances for rheumatology care. <i>Nature Reviews Rheumatology</i> , 2018, 14, 693-703.	3.5	148
10	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. <i>Arthritis Research and Therapy</i> , 2018, 20, 133.	1.6	30
11	T cell immunoregulation in active ocular toxoplasmosis. <i>Immunology Letters</i> , 2017, 184, 84-91.	1.1	9
12	Verteporfin-induced formation of protein cross-linked oligomers and high molecular weight complexes is mediated by light and leads to cell toxicity. <i>Scientific Reports</i> , 2017, 7, 46581.	1.6	53
13	Current and Emerging Treatment for Diabetic Macular Edema. <i>International Ophthalmology Clinics</i> , 2017, 57, 165-177.	0.3	5
14	AICAR suppresses TNF- α -induced complement factor B in RPE cells. <i>Scientific Reports</i> , 2017, 7, 17651.	1.6	9
15	The human immune response to <i>Toxoplasma</i> : Autophagy versus cell death. <i>PLoS Pathogens</i> , 2017, 13, e1006176.	2.1	45
16	Long-term Follow-up and Outcomes in Traumatic Macular Holes. <i>American Journal of Ophthalmology</i> , 2016, 166, 206-207.	1.7	2
17	Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. <i>EBioMedicine</i> , 2016, 5, 198-203.	2.7	106
18	Endogenous Endophthalmitis. , 2016, , 171-184.		0

#	ARTICLE	IF	CITATIONS
19	Scleral Buckle. <i>International Ophthalmology Clinics</i> , 2015, 55, 147-156.	0.3	9
20	Finding the Optimal Treatment Plan for Exudative AMD. <i>International Ophthalmology Clinics</i> , 2015, 55, 103-112.	0.3	4
21	Management of Diabetic Macular Edema. <i>International Ophthalmology Clinics</i> , 2015, 55, 113-122.	0.3	1
22	Toxoplasmic Retinitis. <i>International Ophthalmology Clinics</i> , 2015, 55, 137-145.	0.3	1
23	Long-term Follow-up and Outcomes in Traumatic Macular Holes. <i>American Journal of Ophthalmology</i> , 2015, 160, 1255-1258.e1.	1.7	65
24	The Impact of Cataract Surgery on AMD Development and Progression. <i>Seminars in Ophthalmology</i> , 2014, 29, 301-311.	0.8	13
25	Complications of Subspecialty Ophthalmic Care: Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular Endothelial Growth Factor Pathway. <i>Seminars in Ophthalmology</i> , 2014, 29, 263-275.	0.8	9
26	Complications of Subspecialty Ophthalmic Care: Endophthalmitis after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Medications. <i>Seminars in Ophthalmology</i> , 2014, 29, 257-262.	0.8	26
27	Transcriptional Analysis of Murine Macrophages Infected with Different Toxoplasma Strains Identifies Novel Regulation of Host Signaling Pathways. <i>PLoS Pathogens</i> , 2013, 9, e1003779.	2.1	111
28	Ocular Siderosis. <i>International Ophthalmology Clinics</i> , 2013, 53, 177-184.	0.3	20
29	Choroidal Osteomas. <i>JAMA Ophthalmology</i> , 2013, 131, 124.	1.4	2
30	Interleukin-6 gene polymorphism (rs1744674G/C) is associated with toxoplasmic retinochoroiditis. <i>Acta Ophthalmologica</i> , 2013, 91, e311-4.	0.6	29
31	Choroidal Neovascular Membrane Formation and Retinochoroidopathy in a Patient with Systemic Langerhans Cell Histiocytosis: A Case Report and Review of the Literature. <i>Case Reports in Ophthalmology</i> , 2012, 3, 128-135.	0.3	7
32	Increased serum levels of soluble tumor necrosis factor receptor-2 (sTNFR2) in patients with active toxoplasmic retinochoroiditis. <i>Brazilian Journal of Infectious Diseases</i> , 2012, 16, 540-544.	0.3	5
33	Progressive Outer Retinal Necrosis Presenting as Cherry Red Spot. <i>Ocular Immunology and Inflammation</i> , 2012, 20, 384-386.	1.0	2
34	Evidence for Baseline Retinal Pigment Epithelium Pathology in the Trp1-Cre Mouse. <i>American Journal of Pathology</i> , 2012, 180, 1917-1927.	1.9	34
35	Sympathetic Ophthalmia. <i>Seminars in Ophthalmology</i> , 2011, 26, 316-320.	0.8	55
36	Progression of Diabetic Retinopathy and Maculopathy After Phacoemulsification Surgery. <i>International Ophthalmology Clinics</i> , 2010, 50, 155-166.	0.3	7

#	ARTICLE	IF	CITATIONS
37	Case 33-2010. <i>New England Journal of Medicine</i> , 2010, 363, 1749-1758.	13.9	8
38	Treatment of Acute Retinal Necrosis. <i>Ophthalmology</i> , 2010, 117, 818-824.	2.5	140
39	Genetics of Hereditary Vitreoretinal Degenerations. <i>Seminars in Ophthalmology</i> , 2007, 22, 219-227.	0.8	5
40	Acute Retinal Necrosis: An Overview. <i>International Ophthalmology Clinics</i> , 2007, 47, 145-154.	0.3	30
41	Intraocular Foreign Body Related Endophthalmitis. <i>International Ophthalmology Clinics</i> , 2007, 47, 165-171.	0.3	2
42	RETINAL TOXICITY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE. <i>Retina</i> , 2006, 26, 531-536.	1.0	70
43	Predictors of Visual Outcome and Choroidal Neovascular Membrane Formation After Traumatic Choroidal Rupture. <i>JAMA Ophthalmology</i> , 2006, 124, 957.	2.6	65
44	Treatment Options for Metastatic Tumors to the Choroid. <i>Seminars in Ophthalmology</i> , 2005, 20, 207-216.	0.8	15
45	Sympathetic Ophthalmia. <i>Seminars in Ophthalmology</i> , 2005, 20, 191-197.	0.8	107
46	Vogt-Koyanagi-Harada Disease. <i>Seminars in Ophthalmology</i> , 2005, 20, 183-190.	0.8	122
47	Ocular Manifestations and Treatment of Syphilis. <i>Seminars in Ophthalmology</i> , 2005, 20, 161-167.	0.8	214